Tests PF-07328948 pill in adults with heart failure
Tests a new study pill against a placebo in adults with heart failure.
Plain-language title generated from the registry record
Registry title: A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)
Key facts
- Where
- Barcelona, Córdoba, L'hospitalet De Llobregat, Madrid, Majadahonda, Santiago De Compostela, and Valencia, SpainSee the 12 sites
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to under 80 who have had heart failure for at least 3 months and still have symptoms.
- Age
- 18 years to under 80 years (up to 79 years)
- Sex
- All sexes can join.
- Disease stage
- Heart failure diagnosed at least 3 months ago, with New York Heart Association Class II-IV symptoms and left ventricular ejection fraction greater than 40%. Kansas City Cardiomyopathy Questionnaire-23 Total Symptom Score below 85 and six-minute walking distance greater than 75 meters.
- Earlier treatment
- People with known hypersensitivity to an SGLT2 inhibitor, or a contraindication to one, cannot join.
Main reasons for not taking part
- Type 1 diabetes mellitus or liver cirrhosis
- Any condition that can affect how the medicine is absorbed into the body
- Major surgery planned during the study that affects walking ability, in the study doctor's opinion
- History of heart transplantation, or currently listed for a heart transplant
- Planned use of IV vasodilators and/or inotropes
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 79 years old?
Source: NCT06991257, who can take part
Where in Spain
- Hospital de la Santa Creu i Sant PauBarcelona, SpainTaking people
- Hospital del MarBarcelona, SpainTaking people
- Hospital Universitari Vall d'HebronBarcelona, SpainTaking people
- Hospital Universitario Reina SofiaCórdoba, SpainTaking people
- Bellvitge University HospitalL'hospitalet De Llobregat, SpainTaking people
- Hospital Universitario La PazMadrid, SpainTaking people
- Hospital Universitario Ramón y CajalMadrid, SpainTaking people
- Hospital Universitario Puerta de Hierro de MajadahondaMajadahonda, SpainTaking people
- Fundacion Publica Galega Instituto De Investigacion Sanitaria De Santiago De CompostelaSantiago De Compostela, SpainTaking people
- Consorcio Hospital General Universitario de ValenciaValencia, SpainTaking people
- Hospital Clinico Universitario de ValenciaValencia, SpainTaking people
- Hospital Universitario Y Politecnico La FeValencia, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Pfizer
- Trial code
- NCT06991257EU 2024-518438-94-00
- Record updated
- 23 October 2026
- Original description
The purpose of this study is to learn about the safety and effects of the study medicine (PF-07328948) for the possible treatment of heart failure (HF).Read full original descriptionShow less
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AN ORAL BRANCHED-CHAIN KETOACID DEHYDROGENASE KINASE INHIBITOR, PF-07328948, IN ADULTS WITH HEART FAILURE (BRANCH-HF)
The purpose of this study is to learn about the safety and effects of the study medicine (PF-07328948) for the possible treatment of heart failure (HF).
Inclusion: aged 18 years to < 80 years; clinically confirmed to have a diagnosis of heart failure for at least 3 months; New York Heart Association Class II-IV symptoms; left ventricular ejection fraction greater than 40%; Kansas City Cardiomyopathy Questionnaire-23 Total Symptom Score < 85; Six-minute walking distance greater than 75 meters.
Exclusion: Major surgery scheduled for the duration of the study, affecting walking ability in the opinion of the study doctor; Prior intolerance/known hypersensitivity to an SGLT2 inhibitor or contraindication to an SGLT2 inhibitor; Type 1 diabetes mellitus, liver cirrhosis or any condition that can possibly affect how the medicine is absorbed into the body; History of heart transplantation, or currently listed for a heart transplant, or current planned use of IV vasodilators and/ or inotropes.
This study is seeking participants who are:.